Lytic
General Information
DRACP ID DRACP00338
Peptide Name Lytic
Sequence KLlLKlLkkLLKlLKKK
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin Interleukin-4 receptor a (IL-4Ra) chain
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
BxPC-3 | Pancreatic ductal adenocarcinoma | Carcinoma | IC50=37.1 μmol/L | WST-1 assay | 24 h | 1 |
SU.86.86 | Pancreatic adenocarcinoma | Carcinoma | IC50=28.0 μmol/L | WST-1 assay | 24 h | 1 |
KB | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=37.4 μmol/L | WST-1 assay | 24 h | 1 |
T98G | Glioblastoma | Blastoma | IC50=77.3 μmol/L | WST-1 assay | 24 h | 1 |
A172 | Glioblastoma | Blastoma | IC50=30.5 μmol/L | WST-1 assay | 24 h | 1 |
NCI-H322 | Minimally invasive lung adenocarcinoma | Carcinoma | IC50=27.1 μmol/L | WST-1 assay | 24 h | 1 |
MDA-MB-231 | Breast adenocarcinoma | Carcinoma | IC50=18.5 μmol/L | WST-1 assay | 24 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Targeting Interleukin-4 Receptor α
Affinity Not available
Mechanism The IL-4Rα–lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification l=D-Leucine; k=D-Lysine
Chiral Mix
Physicochemical Information
Formula C72H130N18O8
Absent amino acids ACDEFGHIMNPQRSTVWY
Common amino acids KL
Mass 166152
Pl 11.5
Basic residues 6
Acidic residues 0
Hydrophobic residues 6
Net charge 6
Boman Index -378
Hydrophobicity -3.53
Aliphatic Index 137.65
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 22084165
Title Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy
Doi 10.1158/1535-7163.MCT-11-0363
Year 2012
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available